Betnovate

Betnovate is a brand name for the medication betamethasone, which is a potent corticosteroid used to treat various skin conditions. It belongs to a class of drugs called topical corticosteroids. Here is some information about Betnovate:

Treatment of Skin Conditions

Betnovate (betamethasone) is commonly prescribed for the treatment of various skin conditions, including eczema, psoriasis, dermatitis, and allergic reactions. It works by reducing inflammation, relieving itching, and suppressing the immune response in the affected area of the skin.

Dosage and Application

Betnovate is available as a cream, ointment, or lotion, and the specific form prescribed will depend on the nature and location of the skin condition being treated. It is usually applied to the affected area of the skin once or twice daily, as directed by a healthcare professional. It is important to use the medication exactly as prescribed and to follow the recommended dosage and application instructions.

Duration of Treatment

The duration of Betnovate treatment will vary depending on the specific skin condition and the individual’s response to the medication. In some cases, it may be prescribed for short-term use to control acute flare-ups, while in other cases, it may be used for longer periods to manage chronic conditions. It is important to follow the doctor’s instructions regarding the duration of treatment.

Precautions and Potential Side Effects

Betnovate should be used with caution and under the guidance of a healthcare professional. Prolonged use of potent topical corticosteroids like Betnovate can lead to side effects, such as thinning of the skin, stretch marks, increased hair growth, and skin discoloration. It is important to follow the prescribed duration of treatment and not to use larger amounts or apply it to larger areas of the skin than recommended.

Betnovate should not be used on certain areas of the body, such as the face, groin, or armpits, unless specifically instructed by a healthcare professional. It should not be used on broken or infected skin.

Consultation with Healthcare Professional

Betnovate is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor or dermatologist to evaluate the specific skin condition, determine the appropriate treatment plan, and discuss the usage and potential side effects of Betnovate.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Betnovate or any other medication for the treatment of skin conditions. They will be able to provide specific instructions based on your medical history and individual needs.

References

1. ^ Jump up to:^a b “Betamethasone Use During Pregnancy”. Drugs.com. 30 December 2019. Retrieved 29 March 2020.
2. ^ “Betamethasone 500 microgram Soluble Tablets – Summary of Product Characteristics (SmPC)”. (emc). 5 April 2018. Retrieved 29 March 2020.
3. ^ Jump up to:^{a b c d e f g h i j} “Betamethasone”. The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 2 December 2015.
4. ^ Jump up to:^a b “Betamethasone topical”. The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 2 December 2015.
5. ^ Antignac JP, Le Bizec B, Monteau F, Andre F (January 2002). “Differentiation of betamethasone and dexamethasone using liquid chromatography/positive electrospray tandem mass spectrometry and multivariate statistical analysis”. Journal of Mass Spectrometry. 37 (1): 69–75. Bibcode:2002JMSp…37…69A. doi:10.1002/jms.260. PMID 11813313.
6. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 485. ISBN 9783527607495.
7. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
8. ^ “The Top 300 of 2020”. ClinCalc. Retrieved 7 October 2022.
9. ^ “Betamethasone – Drug Usage Statistics”. ClinCalc. Retrieved 7 October 2022.
10. ^ “Betamethasone Topical”. MedlinePlus. 19 March 2020. Retrieved 29 March 2020.
11. ^ Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, et al. (September 2012). “A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia”. Movement Disorders. 27 (10): 1312–1316. doi:10.1002/mds.25126. PMID 22927201. S2CID 23696748.
12. ^ Moreno G, Corbalán J, Peñaloza B, Pantoja T (September 2014). “Topical corticosteroids for treating phimosis in boys”. The Cochrane Database of Systematic Reviews. 9 (9): CD008973. doi:10.1002/14651858.CD008973.pub2. PMID 25180668.
13. ^ Van Howe RS (October 1998). “Cost-effective treatment of phimosis”. Pediatrics. 102 (4): E43. doi:10.1542/peds.102.4.e43. PMID 9755280. Archived from the original on 19 August 2009. A review of estimated costs and complications of 3 phimosis treatments.
14. ^ Esposito C, Centonze A, Alicchio F, Savanelli A, Settimi A (April 2008). “Topical steroid application versus circumcision in pediatric patients with phimosis: a prospective randomized placebo controlled clinical trial”. World Journal of Urology. Springer Science and Business Media LLC. 26 (2): 187–190. doi:10.1007/s00345-007-0231-2. PMID 18157674. S2CID 8922151.
15. ^ Zampieri N, Corroppolo M, Zuin V, Bianchi S, Camoglio FS (April 2007). “Phimosis and topical steroids: new clinical findings”. Pediatric Surgery International. 23 (4): 331–335. doi:10.1007/s00383-007-1878-x. PMID 17308904. S2CID 22849471.
16. ^ Berdeu D, Sauze L, Ha-Vinh P, Blum-Boisgard C (February 2001). “Cost-effectiveness analysis of treatments for phimosis: a comparison of surgical and medicinal approaches and their economic effect”. BJU International. 87 (3): 239–244. doi:10.1046/j.1464-410x.2001.02033.x. PMID 11167650. S2CID 2161551.
17. ^ Chu CC, Chen KC, Diau GY (September 1999). “Topical steroid treatment of phimosis in boys”. The Journal of Urology. 162 (3 Pt 1): 861–863. doi:10.1097/00005392-199909010-00078. PMID 10458396.
18. ^ Jump up to:^{a b c d e f g} “betamethasone” (PDF). F.A. Davis. 2017. Archived (PDF) from the original on 8 September 2017. Retrieved 7 March 2017.
19. ^ “FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain”. FDA. 23 April 2014. Archived from the original on 11 August 2016. Retrieved 15 August 2016.
20. ^ “Celestone Soluspan- betamethasone acetate and betamethasone sodium phosphate injection, suspension”. DailyMed. 18 November 2019. Retrieved 29 March 2020.